KELYNIAM ACHIEVES RECORD REVENUE & PROFITABILITY FOR 2024
Kelyniam Global (OTC:KLYG), a custom cranial implants manufacturer, reported record financial results for 2024. The company achieved total revenue of $3,328,382, marking a 24.6% increase from $2,672,357 in 2023. Operating income improved significantly to $277,037 from a loss of ($239,166), representing a $515,203 improvement.
The company's EBITDA turned positive at $322,824 compared to a loss of $189,758 in 2023. Key operational achievements included expanding to 15 new hospitals, completing an FDA audit with minor observations, and sponsoring the Skull Base 360 wet lab at the University of Maryland. The company plans to focus on strengthening partnerships, in-licensing products, and pursuing organic growth in 2025, with significant investments planned in sales and business development activities.
Kelyniam Global (OTC:KLYG), un produttore di impianti cranici personalizzati, ha riportato risultati finanziari record per il 2024. L'azienda ha raggiunto un fatturato totale di $3.328.382, segnando un aumento del 24,6% rispetto ai $2.672.357 del 2023. L'utile operativo è migliorato significativamente, passando a $277.037 da una perdita di ($239.166), rappresentando un miglioramento di $515.203.
L'EBITDA dell'azienda è diventato positivo a $322.824 rispetto a una perdita di $189.758 nel 2023. Tra i principali risultati operativi ci sono stati l'espansione in 15 nuovi ospedali, il completamento di un audit FDA con osservazioni minori e il patrocinio del laboratorio pratico Skull Base 360 presso l'Università del Maryland. L'azienda prevede di concentrarsi sul rafforzamento delle partnership, sull'acquisizione di prodotti in licenza e sulla crescita organica nel 2025, con significativi investimenti previsti in attività di vendita e sviluppo commerciale.
Kelyniam Global (OTC:KLYG), un fabricante de implantes craneales personalizados, reportó resultados financieros récord para 2024. La empresa logró un ingreso total de $3,328,382, marcando un aumento del 24.6% desde los $2,672,357 en 2023. El ingreso operativo mejoró significativamente a $277,037 de una pérdida de ($239,166), representando una mejora de $515,203.
El EBITDA de la empresa se volvió positivo en $322,824 en comparación con una pérdida de $189,758 en 2023. Los logros operativos clave incluyeron la expansión a 15 nuevos hospitales, la finalización de una auditoría de la FDA con observaciones menores y el patrocinio del laboratorio práctico Skull Base 360 en la Universidad de Maryland. La empresa planea centrarse en fortalecer asociaciones, licenciar productos y buscar crecimiento orgánico en 2025, con inversiones significativas previstas en actividades de ventas y desarrollo comercial.
Kelyniam Global (OTC:KLYG), 맞춤형 두개골 임플란트 제조업체, 2024년 재무 결과에서 기록적인 성과를 보고했습니다. 이 회사는 총 수익 $3,328,382를 달성하여 2023년의 $2,672,357에 비해 24.6% 증가했습니다. 운영 소득은 $277,037로 개선되어 ($239,166)의 손실에서 벗어났으며, $515,203의 개선을 나타냅니다.
회사의 EBITDA는 2023년의 손실 $189,758에 비해 $322,824로 긍정적으로 전환되었습니다. 주요 운영 성과로는 15개 신규 병원으로의 확장, 경미한 관찰이 있는 FDA 감사 완료, 메릴랜드 대학교의 두개저 360 실습실 후원이 포함됩니다. 회사는 2025년에 파트너십 강화, 제품 라이센스 인수, 유기적 성장 추구에 집중할 계획이며, 판매 및 사업 개발 활동에 대한 상당한 투자가 예정되어 있습니다.
Kelyniam Global (OTC:KLYG), un fabricant d'implants crâniens sur mesure, a annoncé des résultats financiers record pour 2024. L'entreprise a atteint un chiffre d'affaires total de 3 328 382 $, marquant une augmentation de 24,6 % par rapport à 2 672 357 $ en 2023. Le résultat opérationnel s'est considérablement amélioré, atteignant 277 037 $ après une perte de (239 166 $), représentant une amélioration de 515 203 $.
L'EBITDA de l'entreprise est devenu positif à 322 824 $ par rapport à une perte de 189 758 $ en 2023. Les principales réalisations opérationnelles ont inclus l'expansion vers 15 nouveaux hôpitaux, l'achèvement d'un audit de la FDA avec des observations mineures, et le parrainage du laboratoire pratique Skull Base 360 à l'Université du Maryland. L'entreprise prévoit de se concentrer sur le renforcement des partenariats, l'acquisition de produits sous licence et la recherche d'une croissance organique en 2025, avec des investissements significatifs prévus dans les activités de vente et de développement commercial.
Kelyniam Global (OTC:KLYG), ein Hersteller von maßgeschneiderten Schädelimplantaten, hat für 2024 rekordverdächtige Finanzergebnisse gemeldet. Das Unternehmen erzielte einen Gesamtumsatz von $3.328.382, was einem Anstieg von 24,6% gegenüber $2.672.357 im Jahr 2023 entspricht. Das Betriebsergebnis verbesserte sich erheblich auf $277.037 von einem Verlust von ($239.166), was eine Verbesserung von $515.203 darstellt.
Das EBITDA des Unternehmens wurde positiv mit $322.824 im Vergleich zu einem Verlust von $189.758 im Jahr 2023. Zu den wichtigsten betrieblichen Erfolgen gehörten die Expansion auf 15 neue Krankenhäuser, der Abschluss eines FDA-Audits mit geringfügigen Beobachtungen und die Förderung des Skull Base 360 Wet Labs an der Universität von Maryland. Das Unternehmen plant, sich 2025 auf die Stärkung von Partnerschaften, die Lizenzierung von Produkten und das Streben nach organischem Wachstum zu konzentrieren, wobei erhebliche Investitionen in Vertriebs- und Geschäftsentwicklungsaktivitäten geplant sind.
- Revenue increased 24.6% to $3.33M in 2024
- Operating income improved by $515,203 to reach $277,037
- EBITDA turned positive at $322,824 from previous year's loss
- Expanded customer base with 15 new hospitals
- Successfully completed FDA audit with only minor observations
- None.
"Kelyniam had an exceptionally strong year in 2024," stated Ross Bjella, Kelyniam's CEO. "This marks the strongest performance in the company's history both financially and operationally. Our success is attributed to our dedicated team of distributors and to Desiree Webb, Vice President of Operations and Business Development, who has developed a skilled manufacturing team that ensures the timely delivery of high-quality custom PEEK implants."
Financial highlights for the year ended December 31, 2024, compared to the same period in 2023 include:
Total revenue:
Operating income:
EBITDA:
Events that significantly influenced the year included:
- 15 new hospitals purchased implants from Kelyniam in 2024
- Completion of an FDA audit late last year resulting in 5 minor observations, all of which have been addressed
- Sponsorship of the Skull Base 360 wet lab at the University of
Maryland , enhancing relationships with leading teaching institutions
The complete financials are available on the company's website at www.Kelyniam.com.
"We look forward to building on the success of 2024 by strengthening our relationships with current partners, in-licensing products, and pursuing organic growth," Bjella continued. "Kelyniam will significantly invest in sales and business development activities in 2025. The company is well-positioned to partner with foreign companies with cranial surgery products seeking a distribution partner or access to a
Kelyniam Inc., specializes in the rapid production of custom prosthetics utilizing computer aided design and computer aided manufacturing of advanced medical grade polymers. The Company develops, manufactures, and distributes custom cranial and maxillo-facial implants for patients. Kelyniam works directly with surgeons, health systems and payors to improve clinical and cost-of-care outcomes. Kelyniam's web site address is www.Kelyniam.com.
As a cautionary note to investors, certain matters discussed in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; the Company's ability to execute its service and product sales plans; changes in the status of ability to market products; and the risks described from time to time in the Company's SEC reports.
View original content:https://www.prnewswire.com/news-releases/kelyniam-achieves-record-revenue--profitability-for-2024-302402509.html
SOURCE Kelyniam Global Inc
FAQ
What was Kelyniam Global's (KLYG) revenue growth in 2024?
How much did KLYG's operating income improve in 2024?
How many new hospitals did Kelyniam (KLYG) add as customers in 2024?
What was Kelyniam's (KLYG) EBITDA performance in 2024?
What are Kelyniam's (KLYG) growth plans for 2025?
